Stock 002393 TIANJIN LISHENG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Tianjin Lisheng Pharmaceutical Co.,Ltd. Stock

Equities

002393

CNE100000NJ9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
25.01 CNY +1.83% Intraday chart for Tianjin Lisheng Pharmaceutical Co.,Ltd. +0.81% -4.18%
Mar. 22 Tianjin Lisheng Pharmaceutical Co.,Ltd. Proposes Cash Dividend for the Year 2023 CI
Mar. 22 Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains from Asset Disposals; Shares Jump 4% MT

Financials

Sales 2022 1.15B 158M Sales 2023 1.15B 159M Capitalization 4.81B 664M
Net income 2022 93M 12.85M Net income 2023 362M 50M EV / Sales 2022 1.72 x
Net cash position 2022 1.95B 269M Net cash position 2023 2.19B 302M EV / Sales 2023 2.27 x
P/E ratio 2022
41.7 x
P/E ratio 2023
13.2 x
Employees 1,328
Yield 2022
1.41%
Yield 2023
2.3%
Free-Float 44.28%
More Fundamentals * Assessed data

Chart Tianjin Lisheng Pharmaceutical Co.,Ltd.

Dynamic Chart

Latest news about Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Lisheng Pharmaceutical Co.,Ltd. Proposes Cash Dividend for the Year 2023 CI
Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains from Asset Disposals; Shares Jump 4% MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lisheng Pharmaceutical Buys 65% Stake in Qingchun Kangyuan Pharmaceutical for 137 Million Yuan; Shares Up 3% MT
Tianjin Arm Lisheng Pharmaceutical To Buy Chinese Medicine Firm Jiangxi Qingchun Kangyuan MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. agreed to acquire 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. for approximately CNY 140 million. CI
Tianjin Lisheng Pharma Setting Up Venture Capital Fund MT
Lisheng Pharmaceutical and Lisheng Investment Enter into the Partnership Agreement with Bozheng Capital, Tianjin Jinjia and Tianjin Handeway CI
Tianjin Development to Vote Dec. 5 on Lisheng Pharma's Sale of Tianjin Pharmaceutical Finance Stake MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 87.8 million. CI
Lisheng Pharmaceutical's H1 Attributable Profit Jumps MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lisheng Pharmaceutical Subscribes for 20 Million Yuan Wealth Management Product MT
Lisheng Pharma to Receive 247.9 Million Yuan for Relocation MT
More news

Quotes and Performance

1 day+1.83%
1 week+0.81%
Current month+0.60%
1 month+2.46%
3 months+6.52%
6 months+1.09%
Current year-4.18%
More quotes

Highs and lows

1 week
23.40
Extreme 23.4
25.25
1 month
23.40
Extreme 23.4
26.18
Current year
17.66
Extreme 17.66
27.45
1 year
17.66
Extreme 17.66
28.80
3 years
17.66
Extreme 17.66
28.80
5 years
16.46
Extreme 16.46
29.99
10 years
16.46
Extreme 16.46
59.98
More quotes

Managers and Directors - Tianjin Lisheng Pharmaceutical Co.,Ltd.

Managers TitleAgeSince
Fu Jun Wang CEO
 Chief Executive Officer 57 17-11-14
Jia Ying Wang DFI
 Director of Finance/CFO 41 -
Zi Long Liu IRC
 Investor Relations Contact - -
Members of the board TitleAgeSince
Ping Zhang CHM
 Chairman 55 22-11-02
Fu Jun Wang CEO
 Chief Executive Officer 57 17-11-14
Mei Zhang BRD
 Director/Board Member 54 20-12-27
More insiders

ETFs positioned on Tianjin Lisheng Pharmaceutical Co.,Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +1.25% -
More ETFs positioned on Tianjin Lisheng Pharmaceutical Co.,Ltd.

Quotes

Date Price Change Volume
24-04-19 25.01 +1.83% 3,007,796
24-04-18 24.56 +0.66% 1,921,740
24-04-17 24.4 +3.87% 2,039,400
24-04-16 23.49 -3.49% 2,567,001
24-04-15 24.34 -1.89% 2,637,979

End-of-day quote Shenzhen S.E., April 18, 2024

More quotes

Company Profile

Tianjin Lisheng Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of chemical drugs. The Company's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. It distributes its products mainly within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-04-24 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
TIANJIN LISHENG PHARMACEUTICAL CO.,LTD. Stock Tianjin Lisheng Pharmaceutical Co.,Ltd.
-4.18% 636M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.91% 43.82B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+16.96% 21.73B
SANDOZ GROUP AG Stock Sandoz Group AG
+9.05% 13.95B
CIPLA LIMITED Stock Cipla Limited
+7.98% 13.03B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+33.80% 11.13B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.05% 6.8B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+6.64% 5.05B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002393 Stock